Welcome
Support Centre
19 September 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ Print-friendly version ]
The oscillation for acute respiratory distress syndrome (ARDS) treated early trial
ISRCTN ISRCTN87124254
DOI 10.1186/ISRCTN87124254
ClinicalTrials.gov identifier NCT01506401
EudraCT number
Public title The oscillation for acute respiratory distress syndrome (ARDS) treated early trial
Scientific title High frequency oscillation versus best current conventional ventilation to reduce acute respiratory distress syndrome (ARDS) mortality: a multicentre randomised controlled trial
Acronym OSCILLATE
Serial number at source MCT-94829
Study hypothesis What is the effect of early high frequency oscillation (HFO) versus best current conventional ventilation (CV) using HFO only as rescue therapy, on all-cause hospital mortality among patients with severe early acute respiratory distress syndrome (ARDS)?

Please note that as of 29/08/2012, this trial is no longer recruiting patients.
Lay summary Not provided at time of registration
Ethics approval 1. University Health Network (University of Toronto) - approval pending as of 11/05/2009
2. Hamilton Health Sciences (McMaster University) - approval pending as of 11/05/2009

All other centres will seek ethics approval before recruiting participants.
Study design Multicentre randomised controlled trial
Countries of recruitment Canada, Chile, France, Germany, India, Saudi Arabia, Singapore, Spain, United Kingdom, United States of America
Disease/condition/study domain Acute respiratory distress syndrome (ARDS)
Participants - inclusion criteria 1. Acute onset of respiratory failure, with fewer than 2 weeks of new pulmonary symptoms
2. Endotracheal intubation or tracheostomy
3. Hypoxaemia - defined as a partial pressure of oxygen in arterial blood (PaO2)/fraction of inspired oxygen (FiO2) less than or equal to 200 mmHg on FiO2 greater than or equal to 0.5, regardless of positive end expiratory pressure (PEEP)
4. Bilateral alveolar consolidation (airspace disease) seen on frontal chest radiograph
5. Aged 16 years or over, either sex. No upper age limit.

In addition, to qualify for randomisation, patients are assessed on the following ventilator settings:
6. Mode: pressure control or volume control or pressure support
7. FiO2 greater than 0.6 (or higher if necessary to keep pulse oximetric saturation [SpO2] greater than 90%)
8. PEEP greater than 10 cm H2O (or greater if necessary to keep SpO2 greater than 90%)
9. Tidal volume 6 ml/kg predicted body weight (PBW)

After at least 30 minutes on these settings, we sample arterial blood to assess oxygenation. If PaO2 is less than or equal to 200 mmHg, the patient qualifies for randomisation; if PaO2/FiO2 greater than 200 mmHg, standardised hypoxaemia assessments are repeated at least once daily for the following 72 hours (providing the eligibility criteria are still met).
Participants - exclusion criteria 1. Remaining duration of mechanical ventilation less than 48 hours, as judged by the attending physician
2. Primary cause of acute respiratory failure judged by attending physician to be circulatory overload due to, for example, congestive heart failure, hyper-resuscitation, or need for dialysis
3. Suspected pulmonary haemorrhage syndrome
4. Lack of commitment to ongoing life support (note that this does not include the presence of a "Do Not Resuscitate" order alone, if there is a commitment to ongoing life support)
5. Aged less than 16 years
6. Weight less than 35 kg
7. Severe chronic respiratory disease, as indicated by any of:
7.1. Baseline forced expriatory volume in one second (FEV1) less than 20 ml/kg predicted body weight
7.2. Pre-existing chronic interstitial lung disease with chronic interstitial infiltration on chest X-ray
7.3. Documented chronic carbon dioxide (CO2) retention (partial pressure of carbon dioxide in arterial blood [PaCO2] less than 50 mmHg) and/or chronic hypoxaemia (PaO2 less than 55 mmHg on FiO2 = 0.21)
7.4. Chronic restrictive, obstructive, neuromuscular, chest wall or pulmonary vascular disease resulting in severe exercise restriction (e.g., unable to climb stairs or perform household duties), secondary polycythaemia, severe pulmonary hypertension (mean pulmonary artery pressure [PAP] greater than 40 mmHg), or ventilator dependency
8. Morbid obesity - defined as greater than 1 kg/cm body height
9. Underlying pre-existing condition with expected 6-month mortality greater than 50%
10. Neurological conditions with risk of intracranial hypertension (where hypercapnia should be avoided)
11. Neuromuscular disease that will result in prolonged need for mechanical ventilation, including (but not limited to):
11.1. Guillain Barré syndrome
11.2. Cervical spinal cord injury
12. Previous randomisation in this trial
13. All inclusion criteria present for greater than 72 hours in study intensive care unit (ICU)
14. On HFO at the time of screening
Anticipated start date 01/06/2009
Anticipated end date 01/12/2013
Status of trial Completed
Patient information material Not available in web format, please use the contact details below to request a patient information sheet
Target number of participants 1200 (actual number recruited by end of recruitment on 29/08/2012: 548)
Interventions Intervention group: high frequency oscillatory (HFO) ventilation using a lung-open approach and an explicit protocol.
Control group: conventional ventilation using low tidal volumes, a lung-open approach and an explicit protocol, and utilising HFO only as true rescue therapy.

Contact details for joint Principal Investigator:
Dr Maureen Meade
McMaster University
Faculty of Health Sciences
Department of Clinical Epidemiology & Biostatistics, HSC-2C12
1200 Main St W
Hamilton, Ontario
L8N 3Z5
Canada
Tel: +1 905 525 9140 ext. 22160
Fax: +1 905 524 3841
Email: meadema@hhsc.ca
Primary outcome measure(s) All-cause in-hospital mortality
Secondary outcome measure(s) 1. Mortality at other time-points (ICU discharge, 28-day)
2. Barotrauma
3. Organ dysfunction
4. Duration of mechanical ventilation
5. Duration of ICU and hospital stay
6. Quality of life at 6 months
Sources of funding Canadian Institutes of Health Research (CIHR) (Canada) - www.cihr-irsc.gc.ca (ref: MCT-94829)
Trial website
Publications 1. 2013 results in http://www.ncbi.nlm.nih.gov/pubmed/23339639
Contact name Dr  Niall  Ferguson
  Address Toronto Western Hospital
399 Bathurst St., 2MCL-411M
  City/town Toronto
  Zip/Postcode M5T 2S8
  Country Canada
  Tel +1 416 603 6203
  Email n.ferguson@utoronto.ca
Sponsor Canadian Critical Care Trials Group (Canada)
  Address c/o Dr. John Marshall
St. Michael's Hospital
  City/town Toronto
  Zip/Postcode M5M 27K
  Country Canada
  Email caone@smh.toronto.on.ca
  Sponsor website: http://www.ccctg.ca
Date applied 30/04/2009
Last edited 20/02/2013
Date ISRCTN assigned 11/05/2009
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.